Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

NEXT STORY
Cell Culture Market Size to Reach USD 45.12 Billion in 2027 | Rising Demand for Monoclonal Antibodies, Growing Preference for Customized Therapies are Some Major Factors Driving Industry Growth, says Emergen Research
PREV STORY
electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

author_avatar
NASDAQ Market News

Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL

HALIFAX, Nova Scotia, March 28, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

author_avatar
NASDAQ Market News

Global Personalized Medicine Market to 2024: Personalized Cancer Therapy Gets a Boost from Patient-Derived Tumor Organoids

Dublin, Oct. 15, 2018 (GLOBE NEWSWIRE) -- The "Global Personalized Medicine Market - Types, ...

author_avatar
NASDAQ Market News